Lucentis

NICE first fast-track appraisal backs Bayer's Eylea

will compete against Novartis’ already NICE-recommended Lucentis ( ranibizumab).

A new decade of disruption: meeting the biosimilar challgenge

As the dust settles on the first ten years of disruption, the spotlight is now on the future as more leading MAbs, including Humira (adalimumab), MabThera (rituximab), Avastin (bevacizumab) and Lucentis

Promoting off-label use: where to draw the line?

Such an approach would also harm innovation. While the report often cites Lucentis and Avastin as examples of the perceived issue (with some remarks about the drugs' common origin), it does

Novartis' AMD drug pegpleranib fails phase III programme

Plans for Lucentis-boosting duel-therapy stumble as trial data show no additional benefit. ... or wet forms of AMD provided no additional benefit over Lucentis given alone.

Lucentis claims speedy FDA review for myopia complication

The US FDA has said it will use its six-month review process for Roche's Lucentis as a treatment for choroidal neovascularization in patients with severe near-sightedness (myopia). ... If approved, Lucentis could be an important tool in helping these

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]